CMV in Transplant Recipients: Prevention & Management

For transplant recipients, managing Cytomegalovirus (CMV) is a standard but vital part of the recovery process. Because the medications that prevent your body from rejecting a new organ or stem cells also lower your immune defense, CMV can take the opportunity to reactivate or cause a new infection. Your transplant team has a specific “game plan” based on your risk level to keep the virus in check.

Knowing Your Risk: The D/R Status

Your risk level is determined by whether you and your donor have already been exposed to CMV (your serostatus), noted as D (Donor) and R (Recipient). The “highest risk” category depends entirely on the type of transplant you receive:

• Solid Organ Transplants (High Risk = D+/R-): If you are receiving a solid organ (like a kidney or liver), the highest risk is if the donor organ has the virus (D+), but you have never been exposed to it (R-), meaning your body has no “memory” (antibodies) to fight it off ^[1].
• Stem Cell Transplants (High Risk = R+): If you are receiving a stem cell transplant, your own immune system is wiped out during the process. Because of this, being Recipient Positive (R+)—especially if the donor is negative (D-/R+)—is the highest risk scenario because the virus is already inside you waiting to reactivate when your immune system is gone ^[2].
• Low Risk (D-/R-): Neither you nor the donor has the virus, making infection very unlikely unless it is caught from the community after transplant.

Prevention Strategies

There are two main ways transplant teams prevent CMV disease. Your team will choose the one that fits your specific transplant type.

1. Universal Prophylaxis (UP): You take an antiviral pill (like valganciclovir or letermovir) every day for a set period, usually 3 to 6 months ^[3][4]. This acts like a shield while your immune system is at its weakest.
2. Preemptive Therapy (PET): Instead of daily medicine, you have frequent (usually weekly) blood tests called CMV PCR to check your “viral load” ^[5]. If the virus reaches a certain level, you start treatment immediately to stop it before it causes symptoms.

Recognizing the Signs

It is important to know the difference between “general” symptoms and symptoms that mean the virus has invaded a specific organ.

• CMV Syndrome: This feels like a severe flu. Symptoms include fever, extreme fatigue, and low blood cell counts (leukopenia or thrombocytopenia) ^[6][7].
• Tissue-Invasive Disease: This is when the virus attacks a specific part of the body.
  • GI Disease: The most common form, causing persistent diarrhea, abdominal pain, or ulcers in the digestive tract ^[8].
  • Hepatitis: The virus attacks the liver, often seen through abnormal liver function tests.
  • Pneumonia: The virus attacks the lungs, causing shortness of breath and cough.

Advanced Treatments

If the virus becomes difficult to treat or resistant to standard medicines, new options are available. Maribavir is a recently approved drug for refractory (stubborn) CMV that is often easier on the kidneys and bone marrow than older “rescue” medications ^[9][10].

Actionable Tips for Patients

• Track Your Trends: Keep a simple log of your CMV PCR results. Seeing a viral load go from “undetectable” to a low number is common, but a rapidly rising number is something to discuss with your team. To understand these numbers, see our guide on Pathology & Testing.
• Be Mindful of Steroids and Immunosuppression Changes: If your doctor increases your immunosuppression (like giving you a steroid burst to treat rejection), your risk for CMV reactivation goes up. Keep track of these changes and remind your team to adjust your CMV monitoring if your other meds change ^[11].
• Watch Your Blood Counts: Many CMV medicines can lower your white blood cells (neutropenia). If you feel unusually dizzy or see new bruising, report it immediately ^[12].